Inflammatory Bowel Disease News and Research RSS Feed - Inflammatory Bowel Disease News and Research

Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.

There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.
BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin. [More]

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options. [More]

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute. [More]
Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later. [More]

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China. [More]
New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows that the majority of patients with the challenging inflammatory bowel disease, ulcerative colitis (UC), state that the three biggest impacts of the disease on their lives are on their emotional state (in terms of depression, anger or anxiety levels) (76%), ability to get adequate rest/sleep (75%), and taking sick days off work (70%). Those who have had a colectomy (removal of the colon) were more likely to suffer from these impacts. [More]
Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

The Kenneth Rainin Foundation announced today that it will grant $2.2 million to scientists to conduct Inflammatory Bowel Disease (IBD) research. The Rainin Foundation offers support for cutting-edge projects that typically are not eligible for funding from more traditional sources due to their ground-breaking, pioneering nature. [More]
Early exposure to marijuana can lead to immune-related diseases in adulthood

Early exposure to marijuana can lead to immune-related diseases in adulthood

When it comes to using marijuana, new research, involving mice and published in the October 2014 issue of the Journal of Leukocyte Biology, suggests that just because you can do it, doesn't mean that you should. That's because a team of Italian scientists have found that using marijuana in adolescence may do serious long-term damage to the immune system. [More]
Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease. [More]
Patients with particular genetic variation more prone to drug-induced pancreatitis

Patients with particular genetic variation more prone to drug-induced pancreatitis

Doctors have discovered that patients with a particular genetic variation are four times more likely to develop pancreatitis if they are prescribed a widely used group of drugs. [More]
GILZ protein key to preventing bone loss, researchers report

GILZ protein key to preventing bone loss, researchers report

A small protein named GILZ appears to protect against the bone loss that often accompanies arthritis and its treatment, researchers report. [More]
Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Researchers discover genetic factors involved in development of early-onset ulcerative colitis

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

UCLA researchers were part of a team that has discovered the interplay of several genetic factors that may be involved in the development of early-onset ulcerative colitis, a severe type of inflammatory bowel disease. [More]
Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

One in every 200 Ontarians has been diagnosed with inflammatory bowel disease (IBD), with the number of people living with the disease increasing by 64 per cent between 1999 and 2008, according to a study by researchers at the Institute for Clinical Evaluative Sciences, the Children's Hospital of Eastern Ontario, and the Ottawa Hospital Research Institute. [More]
Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness. [More]
Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. [More]
Study finds a host of new clues on gene-environment interactions in Crohn's disease

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America. [More]
Study shows new role for protein APC in suppressing colorectal cancer

Study shows new role for protein APC in suppressing colorectal cancer

A study recently published in the journal Carcinogenesis by researchers at the University of Kansas shows a new role for the protein adenomatous polyposis coli (APC) in suppressing colorectal cancer - the second-leading cause of cancer-related deaths in the U.S. [More]
Scientists create computer algorithm for cell and tissue engineering

Scientists create computer algorithm for cell and tissue engineering

In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies. [More]
23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. [More]